![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NDP |
Gene summary for NDP |
![]() |
Gene information | Species | Human | Gene symbol | NDP | Gene ID | 4693 |
Gene name | norrin cystine knot growth factor NDP | |
Gene Alias | EVR2 | |
Cytomap | Xp11.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q00604 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4693 | NDP | ATC13 | Human | Thyroid | ATC | 3.57e-20 | 6.28e-01 | 0.34 |
4693 | NDP | ATC5 | Human | Thyroid | ATC | 1.50e-26 | 6.65e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
GO:000703322 | Thyroid | ATC | vacuole organization | 100/6293 | 180/18723 | 1.07e-09 | 2.71e-08 | 100 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NDP | SNV | Missense_Mutation | c.307C>A | p.Leu103Met | p.L103M | Q00604 | protein_coding | tolerated(0.18) | probably_damaging(0.998) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
NDP | SNV | Missense_Mutation | rs137852220 | c.362G>T | p.Arg121Leu | p.R121L | Q00604 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NDP | SNV | Missense_Mutation | novel | c.84N>A | p.Ser28Arg | p.S28R | Q00604 | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDP | SNV | Missense_Mutation | c.140N>A | p.Ser47Tyr | p.S47Y | Q00604 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NDP | SNV | Missense_Mutation | c.226N>A | p.Glu76Lys | p.E76K | Q00604 | protein_coding | tolerated(0.15) | benign(0.253) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NDP | SNV | Missense_Mutation | novel | c.80A>G | p.Asp27Gly | p.D27G | Q00604 | protein_coding | tolerated_low_confidence(0.34) | benign(0) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDP | insertion | In_Frame_Ins | novel | c.20_21insGGACTGCCTCTGCAAGAAACA | p.Ala7_Ala8insAspCysLeuCysLysLysHis | p.A7_A8insDCLCKKH | Q00604 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | ||
NDP | SNV | Missense_Mutation | rs104894870 | c.131A>G | p.Tyr44Cys | p.Y44C | Q00604 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-73-4675-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | alimta | PD |
NDP | SNV | Missense_Mutation | c.320G>T | p.Arg107Leu | p.R107L | Q00604 | protein_coding | tolerated(0.05) | probably_damaging(0.993) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NDP | SNV | Missense_Mutation | c.49G>A | p.Val17Met | p.V17M | Q00604 | protein_coding | tolerated_low_confidence(0.1) | benign(0.046) | TCGA-CN-6021-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |